Additional manufacturers in short supply of generic Adderall
12 Oct 2022
At the beginning of September, several manufacturers detailed a shortage of generic Adderall, otherwise known as amphetamine mixed salts, for a variety of dosage amounts. Now it appears that the shortage has reached more manufacturers.
According to the American Society of Health-System Pharmacists (AHSP), shortages for the generic have hit a total of seven manufacturers for both extended and immediate-release capsules.
For the immediate release version of the drug, shortages have been reported by the ASHP from manufacturers including Rhodes, Sandoz and Teva, in several dosage amounts, though none of the companies have reported the reasons behind the shortages. ASHP stated that Teva’s 10, 20 and 30 mg tablets are on backorder and the company estimates a release date for the middle of October or early- to mid-November.
AHSP reported that Sandoz cannot estimate when they will have 10 and 30 mg doses available and Rhodes has 10, 20 and 30 mg doses in limited supply. The 5 and 15 mg doses are also on backorder and there is no confirmation as to when the drug will be available. However, Solco does have doses available at current.
Shortages of the extended release capsules have been reported by several manufacturers including Amneal Pharmaceuticals, Camber Pharmaceuticals, Par Pharmaceuticals, Rhodes, Sun Pharma and Teva, with none of the companies providing additional details on the reason.
Amneal has 15mg doses available. Several dosage amount are also in stock from Lannett, Prasco, Rhodes and Sandoz. The ASHP report shows that Amneal will release more in the 5, 10, 20, 25 and 30 mg dosage amounts sometime this month, while Teva will release supplies as they become available. The rest cannot give a release date at this time, according to the report.
Endpoints News reached out to all the companies involved. Camber and Amneal declined to comment on the matter and Endpoints did not receive comment from the other manufacturers.
Generic Adderall shortages continue as several manufacturers stare down supply squeezes
In early September, Teva, Amneal, Purdue subsidiary Rhodes Pharmaceuticals and Sandoz were the only ones looking at shortages, according to the ASHP.
The current Adderall squeeze, according to a report from Bloomberg, may be caused in part by a rise in prescriptions. This is due to a combination of factors such as increased dosage amounts and wider availability through startup prescription services.
Earlier this year the FDA also sent a warning to two unregistered pharmacies accused of illegally selling Adderall online to customers without a prescription.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.